(NASDAQ: SRZN) Surrozen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.99%.
Surrozen's earnings in 2026 is -$360,499,000.On average, 7 Wall Street analysts forecast SRZN's earnings for 2026 to be -$154,664,074, with the lowest SRZN earnings forecast at -$166,576,315, and the highest SRZN earnings forecast at -$134,953,147. On average, 7 Wall Street analysts forecast SRZN's earnings for 2027 to be -$47,939,222, with the lowest SRZN earnings forecast at -$75,664,788, and the highest SRZN earnings forecast at -$33,159,220.
In 2028, SRZN is forecast to generate -$40,442,405 in earnings, with the lowest earnings forecast at -$53,477,369 and the highest earnings forecast at -$32,915,402.